(BW)(GNI) GNI在福冈创办GNI系统药理学研究所

美国商业新闻2006年3月24日日本福冈和东京消息——

国际性生物制药公司和综合系统药理学领域领先厂商GNI公司上周在福冈开办了GNI系统药理学研究所。新研究所将整合GNI久留米研究实验室和GNI九州大学研究小组的基因网络分析研究工作，以研究所新建的超级计算机支持他们的研究活动。

GNI系统药理学研究所设在福冈系统大规模集成电路（LSI）多功能开发中心，研究所利用生化实验方法和基于系统科学的技术分析药物对人体细胞的作用途径。利用专业化超级计算机和GNI专有的大量人体细胞基因调控数据，中心能够快速分析连接人类基因组的基因调控网络，它们决定对药物和候选药物的反应。因此GNI有能力研制副作用更少、安全性更高的药物，快速发现有效和低风险的药物靶基因。

GNI董事会主席、首席执行官和创始人Christopher Savoie博士说：“我们很高兴创办GNI系统药理学研究所，研究所将成为GNI在英国剑桥大学的实验室和在中国上海睿星基因技术有限公司（Shanghai Genomics）的研究部门之间协作的中心，进一步提高GNI的全球药物研发能力。GNI有能力把日本在半导体、超级计算机和纳米技术方面的领先能力同中国在创新的西方科学和远景研究上的实力组合在一起，意味着它是融合大规模集成电路和生物技术研发活动的先驱，这一领域在不远的将来有望爆发科学突破。”

GNI总裁兼首席运营官、上海睿星公司共同创始人罗楹说：“GNI是现代生物制药公司开展有效的无国界合作、获取最多可用资源的最佳范例。GNI在上海、剑桥和福冈从事的研究开发和药物研发工作意味着公司已很好地定位于持续不断地开发药物并使药物商品化，满足不发达市场，特别是亚洲市场的医疗需要。”

人们现在普遍认为系统大规模集成电路是基因网络计算的关键。GNI已同剑桥大学、东京大学和九州大学并肩合作开发算法和实验数据，这些算法和实验数据共同构成能够检验药物疗效的强有力的分析系统。利用这些远景研究技术，GNI集团和大批领先的医药公司开展了联合研究项目。

关于GNI公司

综合系统药理学领域的领先厂商GNI公司创办于2001年，是一家国际性生物制药公司，在日本、中国、英国和美国有运营机构。GNI用合乎伦理的方法，通过复杂的逆向工程过程，成功绘制了基因调控网络图谱。此外，GNI还成功开发了把这些数据应用于药物研发所需的技术，该技术目前还不被其他公司掌握。2005年6月，GNI和上海睿星基因技术有限公司（Shanghai Genomics）合并，共同运作一个集成药物研发平台，把遗传发现和药物研发结合在一起。欲了解更多信息，请访问网站 www.gene-networks.com 。

联系方式：GNI公司 Ken Suzuki, 03-5425-6363 (CFO) 或者 Gavin Anderson & Company Deborah Hayden or John Short, 03-5404-0640

(BW)(GNI) GNI Launches the GNI Systems Pharmacology Research Institute in Fukuoka

FUKUOKA, Japan & TOKYO--(BUSINESS WIRE)--March 24, 2006--

GNI, the international biopharmaceutical company and leader in the field of integrated systems pharmacology, last week launched the GNI Systems Pharmacology Research Institute in Fukuoka. The new facility will integrate the gene network analytical work being conducted at GNI's Kurume Research Laboratory with the GNI research group at Kyushu University, and support their activities with new in-house supercomputers.

The GNI Systems Pharmacology Research Institute, which combines biochemical experimentation with systems-science based technologies to analyze drug affected pathways in human cells, is located at the Fukuoka System Large Scale Integration (LSI) Multipurpose Development Center. Utilizing specialized supercomputers and vast quantities of GNI proprietary gene regulation data from human cells, the Center is capable of quickly analyzing the regulatory networks across the human genome that determine responses to drugs and drug candidates. This capability allows GNI to develop safer drugs with fewer side effects and to quickly discover effective and low-risk drug target genes.

GNI's Chairman, Chief Executive Officer and founder, Dr. Christopher Savoie, said, "We are delighted to launch the GNI Systems Pharmacology Research Institute, which will operate at the heart of the collaboration between GNI's laboratories at the University of Cambridge in the UK and its research departments within Shanghai Genomics in China to further advance GNI's global drug development capabilities. GNI's ability to combine leading capabilities in semiconductors, supercomputers and nanotechnology in Japan with innovative Western science and advanced research capabilities in China means that it is pioneering the fusion between LSI and biotechnology R&D activities, an area that is expected to spark major scientific breakthroughs in the near future."

Dr. Ying Luo, GNI's President and Chief Operating Officer and co-founder of Shanghai Genomics, added, "GNI is an excellent example of a modern biopharmaceutical company that effectively works without international borders to source the best available resources. The combination of R&D and drug discovery work that GNI is undertaking in Shanghai, Cambridge and here in Fukuoka means that the company is well positioned to continue developing and commercializing drugs to serve the medical needs of underserved markets, particularly those in Asia."

It is now accepted that systems LSI is critical to the calculation of gene networks. GNI has worked alongside the University of Cambridge, the University of Tokyo and Kyushu University to develop algorithms and experimental data that together comprise a powerful analytical system capable of testing the efficacy of drugs. Using this and other advanced research techniques, the GNI group has been engaged in joint research projects with a number of leading pharmaceutical companies.

About GNI

Founded in 2001, GNI, a leader in the field of integrated systems pharmacology, is an international biopharmaceutical company with operations in Japan, China, the U.K. and the U.S. GNI has used ethically approved methods to successfully map the gene regulatory networks via a complex process of reverse engineering. Furthermore, GNI has successfully developed the technology required to apply this data to drug development and discovery, a feat that has not been achieved by any other organization. In June 2005, GNI merged with Shanghai Genomics, which operates an integrated drug discovery platform, combining genetic discovery and drug development. For further information, please visit www.gene-networks.com

CONTACT: GNI Ltd. Ken Suzuki, 03-5425-6363 (CFO) or Gavin Anderson & Company Deborah Hayden or John Short, 03-5404-0640